Lake Forest, CA–(business wire)–Star Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses, today announced the launch of the EVO Implantable Collamer® Lens (EVO) in furthering its mission to offer announced a partnership with actress and beauty entrepreneur Peyton List. To the millions of Americans who suffer from nearsightedness or myopia. EVO is an FDA approved vision correction lens designed to correct/reduce myopia with or without astigmatism. In December 2022, Liszt was implanted with her EVO lenses (EVO surgery) by her primary care doctor, and suffered from torn contacts on set, irritation from makeup-smeared contacts during her beauty routine, and forgetting glasses. And so on, finally putting an end to years of personal eye sight complaints. when she was on the road
Most recently known for her role in the Netflix series Peyton List, cobra kaikicks off an exciting new year with new shows at Paramount Plus. school spiritsTo prepare and focus for a busy 2023, she decided to correct her distance vision by having EVO surgery. This involves adding a small, flexible lens to each eye that does not remove any corneal tissue. Liszt was plagued by the annoyance of her contact lenses both on and off the film set, but following the EVO procedure she now has sharp 20/20 vision. EVO is different from other vision correction surgeries such as LASIK. Because it protects the cornea while providing sharp, clear vision day and night.2,3
“I’ve had vision problems for longer than I used to. The worst part is that I feel my contact lens tear in the middle of the day and I spend the rest of the day with one eye blurry,” said Peyton List. “After learning about vision correction options from my doctor, the EVO appealed to me the most because it has minimal downtime, doesn’t cause dry eye syndrome, and allows my doctor to remove the lenses for peace of mind if needed. .”
Neda Shamie, MD, an ophthalmologist who performed List’s EVO surgery, said: Peyton is amazed at how quickly her vision has improved after a short amount of downtime and I am thrilled for her. ”
Starting this month, a new EVO digital campaign titled “A Pey in the Life” will follow Peyton List through his EVO journey. The videos, authentically shot at various moments, show her the ease of use of her EVO vision correction experience and the benefits she is currently experiencing since her surgery in December 2022.
“Peyton List longed for a day away from vision problems and the daily frustration of contact lenses and glasses on and off set. And she’s amazed at how wonderful her everyday life has become,” said Tom Fringe, President and CEO of Star Surgical. “Peyton List has experienced for himself how short recovery time is with EVO and encourages everyone to get rid of the pain of daily contacts and glasses. We hope that people, inspired by Peyton’s story and why she chose EVO over other vision correction options, will ask their doctors if EVO is an option to follow in her footsteps.”
Myopia is the most common eye disease in the world and its prevalence is rapidly increasing. It is estimated that over 30% of the world’s population (2.6 billion people) have myopia, and this number is projected to rise to 50% of the world’s population by 2050.1
EVO lenses can permanently correct/reduce myopia with or without astigmatism without removing corneal tissue. If necessary, it can be removed by your doctor for added comfort. In EVO surgery, a unique biocompatible flexible lens made of Collamer® is implanted (or added) to the eye between the iris (the colored part of the eye) and the natural lens to correct for astigmatism with or without astigmatism. Corrects/reduces myopia regardless of The EVO procedure takes approximately 20-30 minutes per eye. EVO lenses work in harmony with your natural eye to provide sharp, clear vision, excellent night vision, built-in UV protection, and won’t induce dry eye syndrome in her.2,3,4 Most patients experience improvement in vision immediately after surgery.
EVO ICL lenses are new to the US market, but have been approved, marketed and successfully implanted by ophthalmologists in Europe, Asia and other parts of the world. According to a patient survey, his 99.4% of patients will undergo his EVO ICL surgery again.Five Over 2,000,000 ICLs distributed worldwide.
For more information on EVO Implantable Collamer® Lenses, please visit: https://EVOICL.com.
References:
|
1) |
Holden B, Frick T, Wilson D et al. Global prevalence and temporal trends of myopia and high myopia from 2000 to 2050 (Ophthalmology 2016;123:1036-1042). |
|
|
2) |
Martinez-Plazs E, Lopez-Miguel A, Lopez-De La Rosa A, et al. Effects of EVO+ Visian Phakic Implantable Collar Lenses on Visual Performance and Vision and Quality of Life, Am J Ophthalmol 2021;226: 117–125. |
|
|
3) |
Parkhurst GD. Prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for myopia correction. Klin Ophthalmology. 29 June 2016;10:1209-15. |
|
|
Four) |
Naves, J. Carracedo, G. Cacho-Babillo, I. Diadenosine Nucleotid Measurements as dry eye scores in patients after LASIK and ICL surgery. Presented at the American Society for Cataract and Refractive Surgery (ASCRS) 2012. |
|
|
Five) |
Packer M. Recessed Collar Lens with Central Port: A Review of the Literature. Clinical Ophthalmology 2018: 12: 2427–2438. |
About Star Surgical
With over 40 years of dedicated ophthalmic surgery, STAAR designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide patients with visual freedom by reducing or eliminating reliance on spectacles or contact lenses. All of these lenses are collapsible and allow the surgeon to insert the lenses through a small incision. STAAR’s lenses used in refractive surgery are called Implantable Collamer® Lenses or “ICLs”, including the EVO ICL™ product line. To date he has sold over 2,000,000 of his ICLs and Star sells these lenses in over 75 countries. For more information on ICL, please visit EVOICL.com. Headquartered in Lake He Forest, Calif., Aliso He operates manufacturing and packaging facilities in Viejo, Calif., Monrovia, Calif. and Nidau, Switzerland. For more information, please visit our website www.staar.com.
safe harbor
All statements that are not statements of historical fact are forward-looking statements, including statements regarding any of the following: the safety, efficacy or performance of the product in certain patients; and the underpinnings of any of the above. Statement of assumptions in . Important factors that could cause actual results to differ materially from those indicated in such forward-looking statements include our year on Form 10-K for the year ended December 31, 2021; It includes the risk factors listed under the caption “Risk Factors” in the following report. It has been filed with the Securities and Exchange Commission and is available on the company’s website under the heading “SEC Filings” in the “Investor Relations” section. We disclaim any intention or obligation to update or revise any forward-looking statements as a result of new information or events. These statements are based on expectations and assumptions as of the date of this press release and involve a number of risks and risks that could cause actual results to differ materially from those set forth in the forward-looking statements. Subject to uncertainty.
IMPORTANT SAFETY INFORMATION ABOUT THE EVO ICL
EVO ICL lenses are intended to correct/reduce myopia from -3.0 D to -20.0 D and to treat astigmatism from 1.0 D to 4.0 D. If you have myopia within these ranges, the EVO ICL procedure may improve your distance vision with or without glasses. contact lens. Since the EVO ICL corrects distance vision, it does not eliminate the need for reading glasses. You may need reading glasses at some point, even if you’ve never worn them before. Because EVO ICL implantation is a surgical procedure, you should undergo a complete ophthalmologic examination and discuss EVO ICL procedures, especially potential benefits, risks, and complications with your ophthalmologist before considering EVO ICL procedures. there is. The time required for healing after surgery should be discussed. Complications, although rare, include the need for additional surgical intervention, inflammation, loss of cells from the lining of the cornea, increased intraocular pressure, and cataracts. 2) not meeting the minimum endothelial cell density for age at the time of transplantation; 3) moderate to severe glaucoma; 4) stable vision. not. or 5) if you are pregnant or breastfeeding.
For additional information on potential benefits, risks and complications, visit DiscoverICL.com.
